What does the NCCN recommend for maintenance therapy in patients with multiple myeloma (MM)?

Updated: Sep 30, 2019
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

For maintenance therapy, the NCCN recommends lenalidomide or bortezomib. Although lenalidomide is a category 1 recommendation, the NCCN notes that lenalidomide maintenance appears to be associated with increased risk of secondary cancers; this should be discussed with patients.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!